Drug discovery and delivery in the 21st century

Medical Principles and Practice

Volumn 16, Issue 1, 2006, Pages 1-14

  Triggle, David J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

Artificial cells; Chemical biology; Combinatorial chemistry; Darwin in a test tube; Drug delivery; Drug targets; Genetic code; Genomics; Molecular evolution; Nanotechnology; Pharmacodynamics; Pharmacogenomics; Pharmacokinetics; Systems biology

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; ACETYLCHOLINESTERASE; AMINO ACID; ANTINOCICEPTIVE AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIOMIMETIC MATERIAL; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; CLOZAPINE; DEVAZEPIDE; DIAZEPAM; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GROWTH HORMONE; INSULIN; MUSCLE RELAXANT AGENT; NUCLEOTIDE; PLATELET DERIVED GROWTH FACTOR; POLYMER; R 15; SMALL INTERFERING RNA; TIFLUADOM; TOXIN; TRANSCRIPTION FACTOR E2F; UNINDEXED DRUG; VASCULOTROPIN; VIRUS DNA;

CELL FUNCTION; COMBINATORIAL CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GENETIC CODE; GENOMICS; HUMAN; HYDROGEL; MACHINE; MACROMOLECULE; MOLECULAR BIOLOGY; MOLECULAR EVOLUTION; MOOD DISORDER; NANOTECHNOLOGY; NONHUMAN; ORGANIC CHEMISTRY; PAIN; PHARMACOGENOMICS; PULSATILE DRUG RELEASE; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY; VESICULAR STOMATITIS VIRUS;

DRUG DELIVERY SYSTEMS; DRUG DESIGN;

EID: 33845534905     PISSN: 10117571     EISSN: None     Source Type: Journal    
DOI: 10.1159/000096133     Document Type: Review

References (125)

1. Triggle DJ: Medicines in the 21st century or pills, politics, potions and profits: where is public policy? Drug Dev Res 2003;59:269-291.
2. United Nations Development Program, Human Development Report 2003. www.undp.org
3. Sachs J: The End of Poverty. New York, Penguin Press, 2005.
4. Stiglitz J: Globalization and Its Discontents. New York, Norton, 2003.
5. Evans WE, McLeod HL: Drug therapy: pharmacogenomics - drug disposition, drug targets and side effects. N Engl J Med 2003;348:538-549.
6. Pelz G, Usuka J: From mouse genetics to human therapeutics. Curr Opin Drug Discov Devel 2005;8:253-261.
7. Manning G, Whyte DB, Martinez R, Tinter T, Sudarsanam S: The protein kinase component of the human genome. Science 2002;298:1912-1934.
8. Robinson DR, Wu YM, Lin SF: The protein tyrosine kinase family of the human genome. Oncogene 2000;19:5548-5557.
9. Futreal PA, Coin L, Marshall M, Down T, Hubbard T, Wooster R, Rahman N, Stratton MR: A census of human cancer genes. Nat Rev Cancer 2004;4:177-183.
10. CMR International: New molecular entities (NMEs) first launched in 1991-2000: 2001. www.cmr.org/factofweek/factofweekOld/o91001.html
11. NIHCM Foundation, Washington, DC: Changing patterns of pharmaceutical innovation. 2002, May. www.nihcm.org
12. Milne GM: Pharmaceutical productivity - the imperative for new paradigms. Ann Rep Med Chem 2003;38:383-396.
13. Economist: Prescription for change: a survey of pharmaceuticals. June 18, 2003.
14. Triggle DJ: Pharmaceutical research: for what, for whom? Science and social policies; in Testa B (ed): Pharmacokinetic Profiling in Drug Research: Biological, Physicochemical and Computational Strategies. Basel, Karger, 2006.
15. Innovation and Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. FDA, 2004. www.fda.gov
16. Petsko G: Size doesn't matter. Genome Biol 2001;2:1003.1-1003.2. http://genomebiology.com/2001/2/3/comment/1003
17. Pennisi E: Gene counters struggle to get the right answer. Science 2003;301:1040-1041.
18. Williams M: Systems and integrative biology as alternative guises for pharmacology: prime time for an iPharm concept. Biochem Pharmacol 2005;70:1707-1716.
19. Horrobin DF: Modern biomedical research: an internally self-consistent universe with little contact with medical reality? Nat Rev Drug Discov 2003;2:151-154.
20. Schmid EF, Smith DA: Is pharmaceutical R&D just a game of chance or can strategy make a difference? Drug Discov Today 2004;9:18-26.
21. Knowles J, Gromo G: Target selection in drug discovery. Nat Rev Drug Discov 2003;2:63-69.
22. Abuin A, Holt KH, Platt KA, Sands AT, Zambrowicz BP: Full-speed mammalian genetics: in vivo target validation in the drug discovery process. Trends Biotechnol 2000;20:36-42.
23. Smith C: Drug target validation: hitting the target. Nature 2003;422:341-347.
24. Hart CP: Finding the target after screening the phenotype. Drug Discov Today 2005;10:513-519.
25. Betz UAK: How many genomic targets can a portfolio afford? Drug Discov Today 2005;10:1057-1063.
26. Sams-Dodd F: Target-based drug discovery: is something wrong? Drug Discov Today 2005;10:139-147.
27. Hopkins AL, Groom CR: The druggable genome. Nat Rev Drug Discov 2002;1:727-730.
28. Nolan PM Generation of mouse mutants as tool for functional genomics. Pharmacogenomics 2000;1:243-255.
29. Prendergast G: Knockout drug screen. Nat Biotechnol 2001;19:919-920.
30. Pearson H: Surviving a knockout blow. Nature 2002;415:8-9.
31. Walke DD, Han C, Shaw J, Wann E, Zambrowicz B, Sands A: In vivo drug discovery: identifying the best targets from the genome. Curr Opin Biotechnol 2001;12:626-631.
32. Roses AD, Burns DK, Chissoe S, Middleton L, St Jean P: Disease-specific target selection: a critical first step down the right road. Drug Discov Today 2005;10:177-189.
33. Zambrowicz PP, Sands AT: Knockouts model the 100 best-selling drugs - will they model the next 100? Nat Rev Drug Discov 2003;2:38-51.
34. RNAi Collection: Nat Rev Dec 2003. www.nature.com/reviews/focus/rnai
35. Stevenson M: Therapeutic potential of RNA interference. N Engl J Med 2004;351:1772-1777.
36. Chatterjee-Kishone M, Miller CP: Exploring the sounds of silence: RNAi-mediated gene silencing for target identification and validation. Drug Discov Today 2005;10:1559-1565.
37. Kamath RS, Fraser RG, Dong Y, Poulin G, Durbin R, Gotta M, Kanapin A, LeBot N, Moreno S, Sohrmann M, Welchmann DP, Zipperlen P, Ahringer J: Systematic functional analysis of the Caneorhabditis elegans gene using RNAi. Nature 2003;421:231-237.
38. Ashrafi K, Chang FY, Watts JL, Fraser AG, Kamath RS, Ahringer J, Ruvkin G: Genome-wide RNAi analysis of Caenorhabditis elegans fat regulatory genes. Nature 2003;421:268-272.
39. Stockwell BR: Chemical genetics: ligand-based discovery of gene function. Nat Rev Genet 2000;1:116-125.
40. Szymkowski DE: Chemical genomics versus orthodox drug development. Drug Discov Today 2003;8:157-159.
41. Lokey RS: Forward chemical genetics: progress and obstacles on the path to a new pharmacopeia. Curr Opin Chem Biol 2003;7:91-96.
42. Austin CP: The completed human genome: implications for chemical biology. Curr Opin Chem Biol 2003;7:511-515.
43. Bredel M, Jacoby E: Chemogenomics: an emerging strategy for rapid target and drug discovery. Nat Rev Genet 2004;5:262-275.
44. Thosen W, Leonard J, Behan P: GPCR target validation. Curr Opin Mol Ther 2004;6:640-656.
45. Pope A: Essay on Man. Epistle II. 1688-1674.
46. Souza SC, Frick CP, Wang X, Kopchick JJ, Lobo RB, Goodman HH: A single arginine residue determines specificity of the human growth hormone receptor. Proc Natl Acad Sci USA 1995;92:959-963.
47. Setola V, Roth BL: Why mice are neither miniature humans nor small rats: a cautionary tale involving 5-hydroxytryptamine-6 receptor species variants. Mol Pharmacol 2003;64:1277-1278.
48. Hirst WD, Abrahamsen B, Blaney FE, Calver AR, Aloj L, Price GW, Medhurst AD: Differences in the central nervous system distribution and pharmacology of the 5-hydroxytryptamine-6 receptor compared with rat and human receptors investigated by radioligand binding, site-directed mutagenesis, and molecular modeling. Mol Pharmacol 2003;64:1295-1308.
49. Morphy R, Kay C, Rankovic: From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-651.
50. Morphy R, Rankovic: Designed multiple ligands: an emerging drug discovery paradigm. J Med Chem 2005;48:6523-6543.
51. Roth BL, Sheffler DJ, Kroeze WK: Magic shotguns versus magic bullets selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004;3:353-359.
52. Roth B, Sheffler DJ, Potkin S: Atypical antipsychotic drugs: unitary or multiple mechanisms for 'atypicality'. Clin Neurosci Res, in press.
53. Triggle DJ: Drug targets in the voltage-gated calcium channel family: why some are and some are not. Assay Drug Dev Technol 2003;1:719-733.
54. Csermely P, Agoston V, Pongor S: The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26:178-182.
55. Lombardino JG, Lowe JA: The role of the medicinal chemist in drug discovery - then and now. Nat Rev Drug Discov 2004;3:853-862.
56. Dobson CM: Chemical space and biology. Nature 2004;432:824-865.
57. Wess G, Urmann M, Sickenberger B: Medicinal chemistry: challenges and opportunities. Angew Chem Int Ed Engl 2001;40:3341-3350.
58. MacCoss M, Baillie TA: Organic chemistry in drug discovery. Science 2004;303:1810-1813.
59. Williams M: A return to the fundamentals of drug discovery. Curr Opin Investig Drugs 2004;5:29-33.
60. Krogsgaard-Larsen P, Pelliciari R, De Souza N, Timmerman H, Triggle DJ, van Boeckel CAA, Wasley J: Medicinal chemistry education: what is needed and where is it going? Drug Dev Res 2006;66:1-8.
61. Adams DJ, Alewood PE, Drinkwater RD, Lewis RJ: Conotoxins and their potential therapeutic application. Drug Dev Res 1999;46:219-234.
62. Otto S, Furlan RLE, Sanders JKM: Dynamic combinatorial chemistry. Drug Discov Today 2002;7:117-125.
63. Borman S: The many faces of combinatorial chemistry. Chem Eng News, Dec 27, 2003, pp 45-56.
64. Watson JD, Crick FHC: A structure for deoxyribose nucleic acid. Nature 1953;171:737-738.
65. Kolb HC, Finn MG, Sharpless KB: Click chemistry: diverse chemical function for a few good reactions. Angew Chem Int Ed Engl 2001;40:2004-2021.
66. Lewis WG, Green LG, Grynspzan F, Radic Z, Capelier PR, Taylor P, Finn MG, Sharpless KB: Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew Chem Int Ed Engl 2002;41:1053-1054.
67. Wilson EK: Go forth and multiply. Chem Eng News, Dec 7, 1998, pp 40-44.
68. Wintner EA, Conn MM, Rebek J: Studies in molecular self-replication. Acc Chem Res 1994;27:198-203.
69. Paul N, Joyce GF: A self-replicating ligase ribozyme. Proc Natl Acad Sci USA 2002;99:12733-12740.
70. Joyce GF: Directed molecular evolution. Sci Am, Dec 1992, pp 90-97.
71. Schuster P: Extended molecular evolutionary biology: artificial life bridging the gap between chemistry and biology. Artif Life 1994;1:39-60.
72. Karan I I, Miller BL: Dynamic diversity in drug discovery: putting small-molecule evolution to work. Drug Discov Today 2000;5:67-75.
73. Vasserot AP, Dickinson CD, Tang Y, Huse WD, Manchester KS, Watkins JD: Optimization of protein therapeutics by directed evolution. Drug Discov Today 2003;8:118-126.
74. Henry CM: Special delivery: alternative methods for delivering drugs improve performance, convenience and patient compliance. Chem Eng News, Sept 18, 2000, pp 49-61.
75. Henry CM: Drug delivery: materials scientists look for new materials and ways to manipulate existing ones in order to fulfill unmet needs. Chem Eng News, April 7, 2002, pp 39-47.
76. Henry CM: Breaching barriers: protein transduction and similar methods are promising techniques for delivering a wide variety of drugs directly into cells. Chem Eng News, August 25, 2003, pp 35-55.
77. Henry CM: New wrinkles in drug delivery. Chem Eng News, March 1, 2004, pp 37-42.
78. Singh B, Dahiya M, Saharan V, Ahuja N: Optimizing drug delivery systems using systematic 'design of experiments'. Part II: Retrospect and prospects. Crit Rev Ther Drug Carrier Syst 2005;22:215-294.
79. vander Hoeven BL, Pires NM, Warda HM, Oemrawsingh PV, van Viijmen B, Quax PH, Schalij MJ, vander Wall EE, Jukema JW: Drug-eluting stents: results, promises and problems. Int J Cardiol 2005;99:9-17.
80. Duncan R: The dawning era of polymer therapeutics. Nat Rev Drug Discov 2003;2:347-360.
81. Haag R: Supramolecular drug-delivery systems based on polymeric core-shell architecture. Angew Chem Int Ed Engl 2004;43:278-282.
82. Grayson ACR, Choi IS, Tyler BM, Wang PP, Brem H, Cima MJ, Langer R: Multi-pulse drug delivery from a resorbable polymeric microchip device. Nat Mater 2003;2:767-772.
83. Ehrick JD, Deo SK, Browning TW, Bachas LG, Madov MJ, Daunert S: Genetically engineered protein in hydrogels tailors stimuli-responsiveness characteristics. Nat Mater 2003;4:298-302.
84. Santini JT Jr, Cima MJ, Langer R: A controlled-release microchip. Nature 1999;397:335-338.
85. LaVan DA, McGuire T, Langer R: Small-scale systems for in vivo drug delivery. Nat Biotechnol 2003;21:1184-1191.
86. Sahoo SK, Labhasetwar V: Nanotech approaches to drug delivery and imaging. Drug Discov Today 2003;8:1112-1120.
87. Moghimi SM, Hunter AC, Murray JC: Nanomedicine: current status and future prospects. FASEB J 2005;19:311-330.
88. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 2005;5:161-171.
89. Smith A: Drug delivery systems in the 20th century: merely scratching the surface. PSTT 1999;2:225-227.
90. Langer R, Tirrell DA: Designing materials for biology and medicine. Nature 2004;428:487-492.
91. Sanchez C, Arribart H, Guille MMG: Biomimetism and bioinspiration as tools for the design of innovative materials and systems. Nat Mater 2005;4:277-288.
92. Ma Z, Taylor JS: Nucleic acid-triggered catalytic drug release. Proc Natl Acad Sci USA 2000;97:11159-11163.
93. Kirn DH, McCormick F: Replicating viruses as selective cancer therapeutics. Mol Med Today 1996;2:519-527.
94. Xu Zl, Mizuguchi H, Sakurai F, Koizumi N, Hosono T, Kawabata K, Watanabe Y, Yamaguchi T, Hayakawa T: Approaches to improving the kinetics of adenovirus-delivered genes and gene products. Adv Drug Deliv Rev 2005;57:781-802.
95. Mascola JR: Engineering immune evasion. Nature 2006;441:161-162.
96. Heise C, Kirn DH: Replication-selective adenoviruses as oncolytic agents. J Clin Invest 2000;105:847-851.
97. Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996;274:373-376.
98. Raj K, Ogston P, Beard P: Virus-mediated killing of cells that lack p53 activity. Nature 2001;412:914-917.
99. Ramachandran M, Rahman A, Zou A, Vaillancourt M, Howe JA, Antelman D, Sugarman B, Demers GW, Engler H, Johnson D, Shabram P: Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 2001;19:1035-1041.
100. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004;10:789-799.
101. Triggle DJ: Hijacked receptors. Pharm Acta Helv 2000;74:287-290.
102. Smith AE, Helenius A: How viruses enter animal cells. Science 2004;304:237-257.
103. Blair WS, Lin PF, Meanwell NA, Wallace OB: HIV-1 entry: an expanding portal for drug discovery. Drug Discov Today 2000;5:183-194.
104. Eckert DM, Kim PS: Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001;70:777-810.
105. Schnell MJ, Johnson JE, Buonocore L, Rose JK: Construction of a novel virus that targets HIV-1-infected cells and controls HIV-1 infection. Cell 1997;90:849-857.
106. Beninati C, Oggioni MR, Boccanera M, Sinosa MR, Maggi T, Conti S, Magliani W, De Bernardis F, Teti G, Cassone A, Pozzi G, Polonelli L: Therapy of mucosal candidiasis by expression of an anti-idioype in human commensal bacteria. Nat Biotechnol 2000;18:1060-1064.
107. Kruger C, Hu Y, Pan Q, Marcotte H, Hultberg A, Delwar D, van Dalen PJ, Pouwels PH, Leer RJ, Kelly CG, van Dollenweerd C, Ma JK, Hammarstrom L: In situ delivery of passive immunity by lactobacilli producing single-chain antibodies. Nat Biotechnol 2002;20:702-706.
108. Giomearelli B, Provvedi R, Meacci F, Maggi T, Medaglini D, Pozzi G, Mori T, McMahon JB, Gardella R, Boyd MR: The microbicide cyanovirin-N expressed on the surface of commensal bacterium Streptococcus gordonii captures HIV-1. AIDS 2002;16:1351-1356.
109. Chang TL, Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, Schoolnik GK, Ho DH, Hillier SL, Holodniy M, Lewicki JA, Lee PP: Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci USA 2003;100:11672-11677.
110. Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, Fekete RA, Kar S, Adhya S, Hamer DH: Towards a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci USA 2005;102:11993-11988.
111. Moore JP, Doms RW: The entry of entry inhibitors: a fusion of science and medicine. Proc Natl Acad Sci USA 2003;100:10598-10602.
112. Ferber D: Microbes made to order. Science 2004;303:158-161.
113. Gibbs WW: Synthetic life. Sci Am, May, 2004, pp 75-81.
114. Smith HO, Hutchison CA, Pfannkoch C, Venter JC: Generating a synthetic genome by whole genome assembly: phiX174 bacteriophage from synthetic oligonucleotides. Proc Natl Acad Sci USA 2003;100:15440-15445.
115. Cello J, Paul AV, Wimmer E: Chemical synthesis of poliovirus cDNA: generation of infectious virus in the absence of natural template. Science 2002;297:1016-1018.
116. Hutchison CA, Peterson SN, Gill SR, Cline RT, White O, Fraser CM, Smith HO, Venter JC: Global transposon mutagenesis and a minimal mycoplasma genome. Science 1999;286:2165-2169.
117. Mushegian AR, Koonin EV: A minimal gene set for cellular life derived by comparison of complete bacterial genomes. Proc Natl Acad Sci USA 1996;93:10268-10273.
118. Ji Y, Zhang B, van Horn SF, Warren P, Woodnutt G, Burnham MKR, Rosenberg M: Identification of critical staphylococcal genes using conditional phenotypes generated by antisense RNA. Science 2001;293:2266-2269.
119. Kobyashi K, Ehrlich SD, Albertini A, Amati G, Anderson KK, Arnaud M, Asai K, Ashikaga S, Ayermich S, et al: Essential Bacillus subtilis genes. Proc Natl Acad Sci USA 2003;100:4678-4683.
120. Kodumal SJ, Patel KG, Reid R, Menzella HG, Welch M, Santi DV: Total synthesis of long DNA sequences: synthesis of a contiguous 32-kb polyketide synthase gene cluster. Proc Natl Acad Sci USA 2004;101:15573-15578.
121. Chin JW, Cropp TA, Chu S, Meggers E, Schultz PG: Progress towards an expanded eukaryotic genetic code. Chem Biol 2003;10:511-519.
122. Fenske C, Palm GJ, Hinrichs W: How unique is the genetic code? Angew Chem Int Ed Engl 2003;42:606-610.
123. Wang L, Schultz PG: Expanding the genetic code. Chem Commun (Camb) 2002;1-11.
124. Mehl RA, Anderson JC, Santoro SW, Wang L, Martin AB, King DS, Horn DM, Schultz PG: Generation of a bacterium with a 21 amino acid genetic code. J Am Chem Soc 2003;125:935-939.
125. Triggle DJ: Pharmaceutical sciences in the next millennium. Annals Pharmacother 1999;33:241-246.